<DOC>
	<DOCNO>NCT00672152</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness administer Wilms tumor gene 1 ( WT1 ) cancer peptide . Cancer peptides short piece protein make laboratory like peptide find cancer . These peptide intend give `` vaccine '' activate immune cell person attack his/her cancer . These peptide mix oily substance call Montanide ISA-51 white cell growth factor call Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) may help make immune response stronger .</brief_summary>
	<brief_title>A Phase I Study WT1 Peptides Induce Anti-Leukemia Immune Responses Following Transplantation</brief_title>
	<detailed_description>Two subgroup 2 dose cohort 6 patient enrol exploratory study order attempt obtain immunologic clinical data patient variety hematologic malignancy amongst remission early relapse . The 2 subgroup patient treat different schema depend upon whether undergo undergone autologous allogeneic stem cell transplantation . For autologous transplant patient : Immune monitoring require 90ml peripheral blood first immunization , 3-5 ml leukapheresis product , 40-90ml peripheral blood 4th immunization immunization , last immunization ( week 6-8 ) , discretion immune monitoring lab , every two month immunization continue . For allogeneic transplant patient : Immune monitoring require 90ml peripheral blood first immunization , 40-90ml peripheral blood 4th immunization immunization , last immunization ( week 6-8 ) , discretion immune monitoring lab , every two month immunization continue . Subjects monitor blood pressure , temperature , pulse , pre-injection , 15 30 minute injection , prior allow leave clinic . Diphenhydramine 50 mg , solumedrol 100 mg , epinephrine 1:1000 ( 1 mL ) must available bedside ( clinic code cart must available ) . If hypotension ( SBP &lt; 90mmHg patient baseline SBP &gt; 110mmHg &gt; 20 mmHg decrease baseline SBP &lt; 110 mmHg ) , urticaria orofacial laryngeal edema bronchospasm occur , IV line place diphenhydramine 50 mg , solumedrol 100 mg , epinephrine 1:1000 sq recommend . In event , patient transport emergently emergency room stabilize code team contact patient continue progression symptom worsen hypotension . For fever &gt; 101.5 , acetaminophen 650 mg may give orally .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>There two subgroup patient : Those undergo autologous stem cell transplantation undergo allogeneic stem cell transplantation . Autologous transplant subgroup : Patients follow hematologic malignancy ( AML , CML , ALL , B cell malignancy , myelodysplastic syndrome ) undergo autologous stem cell transplantation . Allogeneic transplantation subgroup : Patients follow hematologic malignancy ( AML , CML , ALL , B cell malignancy , myelodysplastic syndrome ) undergone allogeneic stem cell transplantation . There limitation whether myeloablative nonmyeloablative chemotherapy administer . A 3/6 great match require patient allogeneic stem cell transplant . Both subgroup : Subject must one follow HLA type : HLA A2 , A24 , DR15 DRw53 ( include HLADR4 , DR7 , DRw9 ) Karnofsky performance status must great equal 70 % . Age ≥ 18 year . Ability understand provide sign informed consent fulfills Institutional Review Board guideline . Patient must agree use adequate contraception define : woman , one following ( 1 ) surgical sterilization , ( 2 ) approve hormonal contraceptive ( birth control pill , DepoProvera , Lupron Depot ) , ( 3 ) barrier method ( condom diaphragm ) use spermicide , ( 4 ) intrauterine device ( IUD ) ; men , one following : ( 1 ) surgical sterilization , ( 2 ) condom use spermicide . In order receive immunization , subject : For autologous transplant : At least 2 week prior chemotherapy . Injections 1 2 must complete prior administration growth factor mobilization Injections 3 , 4 , 5 , 6 , resume 2 week time stem cell infusion Grade 3 4 nonhematologic , major organ toxicity within precede 1 week . Nonmajor organ toxicity must resolve grade 2 less . For allogeneic transplant , At least 2 week time stem cell infusion . Without Grade 3 4 nonhematologic major organ toxicity within precede 1 week ; non major organ toxicity must resolve grade 2 less . We require demonstration &gt; 50 % donor myeloid hematopoiesis , base microsatellite polymorphism , prior enrol patient MDS study . Adequate laboratory data follow : Hematologic function : WBC ≥ 3000/microliter , hemoglobin ≥ 9 g/dL ( may transfuse use erythropoietin achieve level ) , platelets ≥ 50,000/microliter ( ( may transfuse ) . Renal hepatic function : serum creatinine &lt; 1.5 mg/dL , bilirubin &lt; 1.5 mg/dL ( except bilirubin &lt; 2.0 permit patent Gilbert 's syndrome ) , SGOT/SGPT &lt; 2 x upper limit normal . Subjects must CD4+ count &gt; 200/mm . There specified requirement CD8+ T cell count . Urine protein/creatinine ratio ( UPC ) must less 1 . Corticosteroid ( great 10mg per day prednisone equipotent dose another corticosteroid ) immunosuppressive therapy within prior 1 week . Pregnant woman nurse mother . Current prior history brain metastasis . More 12 month since stem cell transplant . HIV + , hepatitis BsAg + , Hepatitis C Ab+ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Autologous transplantation</keyword>
	<keyword>Allogeneic transplantation</keyword>
</DOC>